Skyrizi came out on top with the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands. The AbbVie treatment for psoriasis, Crohn’s disease and psoriatic arthritis finished in first ...

As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...

Skyrizi finished atop the Rx and over-the-counter (OTC) pharma brand ad rankings in August, according to data released by iSpot.tv on Wednesday afternoon. Skyrizi generated an impressions share of ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. That’s according to the latest data from real-time TV ad trackers at iSpot.TV, who crunched May’s ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...